These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 16571320)

  • 1. [Trastuzumab improves adjuvant therapy. The Danish Society of Clinical Oncology].
    Andersson M
    Ugeskr Laeger; 2006 Mar; 168(12):1229. PubMed ID: 16571320
    [No Abstract]   [Full Text] [Related]  

  • 2. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J; Perez EA; Pienkowski T; Bell R
    Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current perspective - trastuzumab.
    Hall PS; Cameron DA
    Eur J Cancer; 2009 Jan; 45(1):12-8. PubMed ID: 19042123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Herceptin-based therapy for breast cancer].
    Tokuda Y; Saito Y; Suzuki Y
    Nihon Rinsho; 2006 Mar; 64(3):540-5. PubMed ID: 16529047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adjuvant therapy with trastuzumab in primary breast neoplasms--findings and validity of--opinion on the competence of the Central Oncology section of the North German Society].
    Huober J
    Zentralbl Gynakol; 2006 Jun; 128(3):187; author reply 187-8. PubMed ID: 16812944
    [No Abstract]   [Full Text] [Related]  

  • 7. Trastuzumab and breast cancer. Are we just beyond the prologue of a fascinating story?
    Puglisi F; Piccart M
    Onkologie; 2005 Nov; 28(11):547-9. PubMed ID: 16249638
    [No Abstract]   [Full Text] [Related]  

  • 8. [Medical treatment of primary breast cancer: new targeted biological treatments].
    Andersson M; Nielsen DL
    Ugeskr Laeger; 2007 Sep; 169(37):3082-4. PubMed ID: 17877953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant trastuzumab use in high-risk breast cancer patients may prevent development of contralateral estrogen receptor-negative breast tumors.
    Altundag K; Altundag O; Islam R; Gundeslioglu O
    Med Hypotheses; 2006; 66(5):1045-6. PubMed ID: 16043302
    [No Abstract]   [Full Text] [Related]  

  • 10. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
    Castrellon AB; Glück S
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Adjuvant therapy of breast cancer with trastuzumab].
    Beneder C; Marth C
    Gynakol Geburtshilfliche Rundsch; 2008; 48(3):138-42. PubMed ID: 18566530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent research.
    Goel S; Chirgwin J; Francis P; Stuart-Harris R; Dewar J; Mileshkin L; Snyder R; Michael M; Koczwara B
    Breast; 2011 Apr; 20(2):101-10. PubMed ID: 21183347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer].
    Fagnani F; Colin X; Arveux P; Coudert B; Misset JL
    Bull Cancer; 2007 Jul; 94(7):711-20. PubMed ID: 17723955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neo(adjuvant) trastuzumab treatment: current perspectives.
    Iwata H
    Breast Cancer; 2009; 16(4):288-94. PubMed ID: 19609648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
    Yaal-Hahoshen N; Safra T
    Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
    [No Abstract]   [Full Text] [Related]  

  • 16. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.
    Viani GA; Afonso SL; Stefano EJ; De Fendi LI; Soares FV
    BMC Cancer; 2007 Aug; 7():153. PubMed ID: 17686164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Facts and controversies in the use of trastuzumab in the adjuvant setting.
    Dinh P; de Azambuja E; Cardoso F; Piccart-Gebhart MJ
    Nat Clin Pract Oncol; 2008 Nov; 5(11):645-54. PubMed ID: 18779850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Trastuzumab treatment for breast cancer].
    Yamashiro H; Toyama K; Bando H; Saji S; Toi M
    Nihon Rinsho; 2004 Jul; 62(7):1305-11. PubMed ID: 15283148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial.
    Purmonen TT; Pänkäläinen E; Turunen JH; Asseburg C; Martikainen JA
    Acta Oncol; 2011 Apr; 50(3):344-52. PubMed ID: 21299447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant trastuzumab for breast cancer: editorial does not mention health economics of drug.
    McLaren EH
    BMJ; 2005 Nov; 331(7526):1203. PubMed ID: 16293854
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.